Filament Health with Tim Regan, Jesse Redmond and Ben Lightburn

Filament Health CEO Ben Lightburn joins WTR's Tim Regan and Jesse Redmond to discuss Filament's exclusive focus on naturally derived psychedelics and what sets it apart from other psychedelics drug developers. Lightburn reviews the characteristics of Filament's in-house drug development programs and talks about its expanding partnership network and the benefits it brings to the company. The podcast also covers the reasons behind the recently announced merger agreement with SPAC Jupiter Acquisition Corp.